-+ 0.00%
-+ 0.00%
-+ 0.00%

Halozyme Therapeutics Director Matthew L. Posard Reports Sale of 5,000 Common Shares for $482,146.60

PUBT·11/18/2026 23:48:47
Listen to the news
Halozyme Therapeutics Director Matthew L. Posard Reports Sale of 5,000 Common Shares for $482,146.60
  • Halozyme Therapeutics director Matthew L. Posard sold 5,000 shares of Common Stock on Nov. 18, 2026.
  • The sales comprised 3,400 shares at $96.173 per share and 1,600 shares at $96.974 per share.
  • Posard directly owned 48,609 shares following the transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000149), on November 18, 2026, and is solely responsible for the information contained therein.